FierceBiotech5d
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
Boehringer Ingelheim faces second hung jury in Chicago Zantac trial
The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...
ENDPOINTS NEWS5d
Boehringer plans NDA fil­ing for pul­monary fi­bro­sis drug fol­low­ing Phase 3 da­ta
A Phase 3 trial investigating Boehringer Ingelheim’s nerandomilast in idiopathic pulmonary fibrosis hit its primary endpoint, ...
BioWorld2d
Boehringer Ingelheim divulges new NOX4 inhibitors
Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized NADPH oxidase 4 (NOX4) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, pulmonary hypertension, inflammatory ...
GlobalData on MSN11d
Boehringer Ingelheim reports positive results from trial of HER2 lung cancer drug
The trial met its primary endpoint, showing a meaningful objective response rate and a tolerable safety profile for ...
Boehringer, GSK, Pfizer Still Face Zantac Cases Despite Mistrial
An Illinois mistrial involving the recalled medication Zantac is the latest court decision involving the recalled drug, but ...
FierceBiotech12d
Boehringer and Bayer's oral meds deliver in early HER-2 mutant lung cancer studies
Some patients with non-small cell lung cancer (NSCLC) have mutations in a gene called human epidermal growth factor receptor 2 (HER2), which drives their disease progression. | Some patients with ...